IMTX Immatics NV

Houston, Texas and Tuebingen, Germany, October 4, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced upcoming oral and poster presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer in Houston, Texas from November 6 - 10, 2024.

Full abstracts will be available on November 5, 2024, at 9:00 am EST in the JITC Supplement.

Oral Presentations

Date / Time: November 8, 2024 / 3:50 – 5:25 pm Central Standard TimeSession: Oral Abstract Session 1Abstract Number: 687Title: ACTengine IMA203 TCR-T targeting PRAME shows deep and durable anti-tumor activity in heavily pretreated solid cancer patients Presenter: Martin Wermke, M.D. (University Hospital Dresden, Germany)

Date / Time: November 9, 2024 / 12:30 PM - 1:30 pm Central Standard TimeSession: Rapid Oral - Clinical 2Abstract Number: 661Title: Enhanced pharmacology data of next-generation IMA203CD8 TCR-T monotherapy targeting PRAMEPresenter: Dejka M. Araujo, M.D. (MD Anderson Cancer Center, Houston, Texas, USA)

Poster Presentations

Date: November 8, 2024 Poster Number: 355 Title: An approach to bridging starting materials to monitor T cell persistence in adoptive T cell therapyPresenter: Jourdan Andersson, Ph.D. (Immatics)

Date: November 9, 2024 Poster Number: 226 Title: An effective donor screening program for manufacturing of allogeneic γδ T cell productsPresenter: Inbar Azoulay Alfaguter, Ph.D. (Immatics)

Date: November 9, 2024 Poster Number: 228 Title: Optimizing and streamlining the manufacturing of Vγ9Vδ2 γδ T cells for allogeneic therapyPresenter: Pooja Mehta, Ph.D. (Immatics)

Date: November 9, 2024 Abstract Number: 360 Title: Combination of a TCR-engineered autologous PRAME-targeting T cell therapy with a PRAME-encoding mRNA for the treatment of solid tumorsPresenter: Fabian Brunk, Ph.D. (Immatics)

Date: November 9, 2024 Poster Number: 372 Title: TCR-engineered T cells exhibit enhanced persistence and serial killing ability when armored with membrane-bound IL-15Presenter: Justin Gunesch, Ph.D. (Immatics)

About IMA203 and Target PRAMEACTengine® IMA203 T cells are directed against an HLA-A*02-presented peptide derived from preferentially expressed antigen in melanoma (PRAME), a protein frequently expressed in a large variety of solid cancers, thereby supporting the program’s potential to address a broad cancer patient population. Immatics’ PRAME peptide is present at a high copy number per tumor cell and is homogeneously and specifically expressed in tumor tissue. The peptide has been identified and characterized by Immatics’ proprietary mass spectrometry-based target discovery platform, XPRESIDENT®. Through its proprietary TCR discovery and engineering platform XCEPTOR®, Immatics has generated a highly specific T cell receptor (TCR) against this target for its TCR-based cell therapy approach, ACTengine® IMA203.

ACTengine® IMA203 TCR-T is currently being evaluated in Phase 1 IMA203 monotherapy, and IMA203CD8 (GEN2) monotherapy, where IMA203 engineered T cells are co-transduced with a CD8αβ co-receptor.

About ImmaticsImmatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.

Immatics intends to use its website www.immatics.com as a means of disclosing material non-public information. For regular updates you can also follow us on X, Instagram and LinkedIn.

For more information, please contact:

Attachment

• PDF Version

Immatics NV (NASDAQ:IMTX)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024

Immatics NV (NASDAQ:IMTX)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024